Monthly Archives: March 2014

Cancer Stem Cells: Achilles #39; Heel of Tumors
Faris Farasatti, PhD, PharmD, of the University of Kansas, speaks on the use of cancer stem cells in targeting and treating mesothelioma and cancer in general.

By: Mesothelioma Applied Research Foundation

Continued here:
Cancer Stem Cells: Achilles' Heel of Tumors - Video

Charles Q. Choi

A virus that invaded the genomes of humanity's ancestors millions of years ago now plays a critical role in the embryonic stem cells from which all cells in the human body derive, new research shows.

The discovery sheds light on the role viruses play in human evolution and could help scientists better understand how to use stem cells in advanced therapies or even how to convert normal cells into stem cells.

Embryonic stem cells are pluripotent, meaning they are capable of becoming any other kind of cell in the body. Scientists around the world hope to use this capability to help patients recover from injury and disease.

Researchers have struggled for decades to figure out how pluripotency works. These new findings reveal that "material from viruses is vital in making human embryonic stem cells what they are," said computational biologist Guillaume Bourque at McGill University in Montreal, a co-author of the study published online March 30 in Nature Structural & Molecular Biology.

Viral Invasion

To make copies of itself, a virus has to get inside a cell and co-opt its machinery. When one type of virus called a retrovirus does this, it slips its own genes into the DNA of its host cell. The cell is then tricked into assembling new copies of the retrovirus. The most infamous retrovirus is HIV, the virus behind AIDS.

In rare cases, retroviruses infect sperm or egg cells. If that sperm or egg becomes part of a person, their cells will contain retrovirus DNA, and they can pass that DNA on to their descendants. Past research suggests that at least 8 percent of the human genome is composed of these so-called endogenous retroviruses-leftovers from retroviral infections our ancestors had millions of years ago.

Scientists long thought that endogenous retroviruses were junk DNA that didn't do anything within the human genome, said study co-author Huck-Hui Ng, a molecular biologist at the Genome Institute of Singapore.

However, recent studies have revealed that might not be true for one class of endogenous retroviruses known as human endogenous retrovirus subfamily H. HERV-H DNA was surprisingly active in human embryonic stem cells but not in other regular types of human cells.

See the original post here:
Ancient Virus DNA Gives Stem Cells the Power to Transform

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

"Our results show that this stem cell treatment is safe and it improves heart function when compared to placebo," said Anders Bruun Mathiasen, M.D., research fellow in the Cardiac Catherization Lab at Rigshospitalet University Hospital Copenhagen, and lead investigator of the study. "This represents an exciting development that has the potential to benefit many people who suffer from this common and deadly disease."

Ischemic heart disease, also known as coronary artery disease, is the number one cause of death for both men and women in the United States. It results from a gradual buildup of plaque in the heart's coronary arteries and can lead to chest pain, heart attack and heart failure.

The study is the largest placebo-controlled double-blind randomized trial to treat patients with chronic ischemic heart failure by injecting a type of stem cell known as mesenchymal stromal cells directly into the heart muscle.

Six months after treatment, patients who received stem cell injections had improved heart pump function compared to patients receiving a placebo. Treated patients showed an 8.2-milliliter decrease in the study's primary endpoint, end systolic volume, which indicates the lowest volume of blood in the heart during the pumping cycle and is a key measure of the heart's ability to pump effectively. The placebo group showed an increase of 6 milliliters in end systolic volume.

The study included 59 patients with chronic ischemic heart disease and severe heart failure. Each patient first underwent a procedure to extract a small amount of bone marrow. Researchers then isolated from the marrow a small number of mesenchymal stromal cells and induced the cells to self-replicate. Patients then received an injection of either saline placebo or their own cultured mesenchymal stromal cells into the heart muscle through a catheter inserted in the groin.

"Isolating and culturing the stem cells is a relatively straightforward process, and the procedure to inject the stem cells into the heart requires only local anesthesia, so it appears to be all-in-all a promising treatment for patients who have no other options," Mathiasen said.

Although there are other therapies available for patients with ischemic heart disease, these therapies do not help all patients and many patients continue to face fatigue, shortness of breath and accumulation of fluid in the lungs and legs.

Previous studies have shown mesenchymal stromal cells can stimulate repair and regeneration in a variety of tissues, including heart muscle. Mathiasen said in the case of ischemic heart failure, the treatment likely works by facilitating the growth of new blood vessels and new heart muscle.

The study also supports findings from previous, smaller studies, which showed reduced scar tissue in the hearts of patients who received the stem cell treatment, offering additional confirmation that the treatment stimulates the growth of new heart muscle cells.

The rest is here:
New human trial shows stem cells are effective for failing hearts: Bone marrow-derived stem cells injected directly ...

PUBLIC RELEASE DATE:

31-Mar-2014

Contact: Beth Casteel bcasteel@acc.org 202-375-6275 American College of Cardiology

WASHINGTON (March 31, 2014) Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

"Our results show that this stem cell treatment is safe and it improves heart function when compared to placebo," said Anders Bruun Mathiasen, M.D., research fellow in the Cardiac Catherization Lab at Rigshospitalet University Hospital Copenhagen, and lead investigator of the study. "This represents an exciting development that has the potential to benefit many people who suffer from this common and deadly disease."

Ischemic heart disease, also known as coronary artery disease, is the number one cause of death for both men and women in the United States. It results from a gradual buildup of plaque in the heart's coronary arteries and can lead to chest pain, heart attack and heart failure.

The study is the largest placebo-controlled double-blind randomized trial to treat patients with chronic ischemic heart failure by injecting a type of stem cell known as mesenchymal stromal cells directly into the heart muscle.

Six months after treatment, patients who received stem cell injections had improved heart pump function compared to patients receiving a placebo. Treated patients showed an 8.2-milliliter decrease in the study's primary endpoint, end systolic volume, which indicates the lowest volume of blood in the heart during the pumping cycle and is a key measure of the heart's ability to pump effectively. The placebo group showed an increase of 6 milliliters in end systolic volume.

The study included 59 patients with chronic ischemic heart disease and severe heart failure. Each patient first underwent a procedure to extract a small amount of bone marrow. Researchers then isolated from the marrow a small number of mesenchymal stromal cells and induced the cells to self-replicate. Patients then received an injection of either saline placebo or their own cultured mesenchymal stromal cells into the heart muscle through a catheter inserted in the groin.

"Isolating and culturing the stem cells is a relatively straightforward process, and the procedure to inject the stem cells into the heart requires only local anesthesia, so it appears to be all-in-all a promising treatment for patients who have no other options," Mathiasen said.

Here is the original post:
New human trial shows stem cells are effective for failing hearts

PHILADELPHIA -

Coronary artery disease is the most common cause of heart attacks and death in the world. Plaque builds up in the arteries, reducing blood flow to the heart.

Now, a new experimental treatment could help improve blood flow to the heart and even repair it after a heart attack, making those like Debbie Minch thankful for each day.

"Grace is what's carried me through this," Minch said.

Ten years ago, at just 49, the choir singer and her husband were told she would need a quadruple bypass.

"Now we are at the point where my heart is severely damaged and nothing is really helping," Minch said.

Doctors said a heart transplant was her only option, but she'll soon find out if she'll be accepted into a new trial that could use her own stem cells to help repair the once thought irreversible damage, "or even create new blood vessels within areas of the heart that have been damaged," said Dr. Jon George, interventional cardiologist, Temple University School of Medicine.

First, stem cells are taken from a patient's bone marrow. Then using a special catheter and 3D mapping tool, the cells are injected directly into the damaged tissue.

"We have results from animal data that show blood vessels regrow in the patients that actually get stem cell therapy," George said.

It's a possible answer to Minch's prayers.

See the article here:
Health Beat: Stem cells to the rescue: Repairing the hearts